Page last updated: 2024-12-06

tetrazepam

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

tetrazepam: structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID25215
CHEMBL ID2105527
CHEBI ID135198
SCHEMBL ID157998
MeSH IDM0046648

Synonyms (45)

Synonym
cb 4261
4261 cb
dea no. 2886
tetrazepamum [inn-latin]
7-chloro-5-(cyclohexen-1-yl)-1,3-dihydro-1-methyl-2h-1,4-benzodiazepin-2-one
clinoxan
musaril
einecs 233-837-7
ro 06-6657
7-chloro-5-(1-cyclohexenyl)-1-methyl-2-oxo-2,3-dihydro-1h-(1,4)-benzo(f)diazepine
brn 0890548
myolastan
7-chloro-5-(1-cyclohexen-1- yl)-1,3-dihydro-1-methyl-2h-1,4-benzodiazepin-2-one
tetrazepam
2h-1,4-benzodiazepin-2-one, 7-chloro-5-(1-cyclohexen-1-yl)-1,3-dihydro-1-methyl-
tetrazepam (inn)
myolastan (tn)
D07277
10379-14-3
CHEBI:135198
7-chloro-5-(cyclohexen-1-yl)-1-methyl-3h-1,4-benzodiazepin-2-one
tetrazepam [inn:ban:dcf]
tetrazepamum
fo92091vp8 ,
5-24-04-00064 (beilstein handbook reference)
unii-fo92091vp8
tetrazepam [who-dd]
tetrazepam [mart.]
tetrazepam [inn]
tetrazepam [mi]
tetrazepam [ep monograph]
cb-4261
CHEMBL2105527
SCHEMBL157998
IQWYAQCHYZHJOS-UHFFFAOYSA-N
7-chloro-5-(1-cyclohexen-1-yl)-1-methyl-1,3-dihydro-2h-1,4-benzodiazepin-2-one #
DTXSID00146058
7-chloro-5-(cyclohex-1-en-1-yl)-1-methyl-2,3-dihydro-1h-1,4-benzodiazepin-2-one
CS-6656
HY-101615
tetrazepam 0.1 mg/ml in methanol
Q421104
DB13324
7-chloro-5-(cyclohex-1-en-1-yl)-1-methyl-1,3-dihydro-2h-benzo[e][1,4]diazepin-2-one
tetrazepam, 1mg/ml in acetonitrile

Research Excerpts

Overview

Tetrazepam is a 1,4-benzodiazepine (BZD) derivative which, in rodents, appears to have very little sedative and ataxic effects. It is widely used in Spain as a muscle relaxant, with occasional cutaneous side effects.

ExcerptReferenceRelevance
"Tetrazepam is a muscle relaxant belonging to the benzodiazepine group. "( Occupational allergic contact dermatitis from tetrazepam in nurses.
Goossens, A; Kerre, S; Vander Hulst, K, 2010
)
2.06
"Tetrazepam is a benzodiazepine that is widely used in Spain as a muscle relaxant, with occasional cutaneous side effects. "( Acute generalized exanthematous pustulosis due to tetrazepam.
Alves-Ferreira, J; Barranco, P; Bellón, T; Martín-Esteban, M; Morel, E; Padial, A; Tapia, B; Thomas, E, 2008
)
2.04
"Tetrazepam is a benzodiazepine derivative clinically used as a muscle relaxant. "( Relaxant effect of tetrazepam on rat uterine smooth muscle: role of calcium movement.
Herrera, MD; Marhuenda, E; Perez-Guerrero, C, 1996
)
2.07
"Tetrazepam is a 1,4 benzodiazepine (BZD) clinically used in France and Germany as a muscle relaxant. "( Comparative study in mice of tetrazepam and other centrally active skeletal muscle relaxants.
Biziere, K; Keane, PE; Simiand, J; Soubrie, P,
)
1.87
"Tetrazepam is a 1,4-benzodiazepine (BZD) derivative which, in rodents, appears to have very little sedative and ataxic effects. "( Tetrazepam: a benzodiazepine which dissociates sedation from other benzodiazepine activities. II. In vitro and in vivo interactions with benzodiazepine binding sites.
Bachy, A; Biziere, K; Keane, PE; Morre, M, 1988
)
3.16

Toxicity

ExcerptReferenceRelevance
" The potential concomitant changes in the reporting of adverse reactions concerning these alternatives have been studied less often."( Impact of Medicine Withdrawal on Reporting of Adverse Events Involving Therapeutic Alternatives: A Study from the French Spontaneous Reporting Database.
Arnaud, M; Bégaud, B; Bezin, J; Haramburu, F; Pageot, C; Pariente, A; Salvo, F; Smith, A, 2017
)
0.46
"The objective of this study was to analyse the changes in the reporting of adverse events (AEs) for therapeutic alternatives after the withdrawal of three medicines (dextropropoxyphene, pioglitazone and tetrazepam) from the market for safety reasons."( Impact of Medicine Withdrawal on Reporting of Adverse Events Involving Therapeutic Alternatives: A Study from the French Spontaneous Reporting Database.
Arnaud, M; Bégaud, B; Bezin, J; Haramburu, F; Pageot, C; Pariente, A; Salvo, F; Smith, A, 2017
)
0.64

Pharmacokinetics

Tetrazepam is eliminated with a half-life of 22 +/- 4 h and can be classified as a benzodiazepine with medium half- life value. It seems reasonable, at least from the pharmacokinetic point of view, to attribute pharmacologic activity of tetrazepAM mainly to the parent drug.

ExcerptReferenceRelevance
" Tetrazepam is eliminated with a half-life of 22 +/- 4 h and can be classified as a benzodiazepine with medium half-life value."( Plasma levels and pharmacokinetics of single and multiple dose of tetrazepam in healthy volunteers.
Al-Mallah, NR; Berger, Y; Bun, H; Cano, JP; Necciari, J; Philip, F; Serradimign, A, 1987
)
1.42
" Therefore it seems reasonable, at least from the pharmacokinetic point of view, to attribute pharmacologic activity of tetrazepam mainly to the parent drug."( Biotransformation and pharmacokinetics of tetrazepam in man.
Baumgärtner, MG; Cautreels, W; Langenbahn, H, 1984
)
0.74

Dosage Studied

ExcerptRelevanceReference
" The dosage was optimized corresponding to the clinical symptoms."( [Comparative double-blind study of the effectiveness and tolerance of baclofen, tetrazepam and tizanidine in spastic movement disorders of the lower extremities].
Paulig, M; Pellkofer, M, 1989
)
0.5
" Clinical experience has shown that a decline of the increased muscular tonus in the affected segment mitigates subjective complaints, in particular pain, if the dosage and time of administration are adjusted for every individual patient."( [Therapeutic effect of Myolastan on increased muscle tone of various etiologies].
Adam, P; Obenberger, J; Seidl, Z, 1998
)
0.3
" The dose-response curve was bell-shaped for serum lipids changes, whereas no clear dose-response relationship for blood glucose level modifications could be established."( Effects of acute intraperitoneal administration of tetrazepam on blood glucose level and serum lipids in hyperlipidemic albino rats.
Cuparencu, B; Horák, A; Horák, J,
)
0.38
" Considering the important forensic implication of this finding, a study was conducted with volunteers receiving a single or repeated dosage of Myolastan."( Detection of diazepam in urine, hair and preserved oral fluid samples with LC-MS-MS after single and repeated administration of Myolastan and Valium.
De Boeck, G; Fernandez, Mdel M; Laloup, M; Maes, V; Samyn, N; Vanbeckevoort, Y; Wood, M, 2007
)
0.34
" The mean prescribed dosage was 15 DDD and increased by age up to 43 DDD in women and 30 DDD in men ≥80 years."( Frequency of tetrazepam prescription: estimates for Germany.
Kuepper-Nybelen, J; Schubert, I; Thuermann, P, 2014
)
0.77
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
benzodiazepineA group of heterocyclic compounds with a core structure containing a benzene ring fused to a diazepine ring.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Research

Studies (80)

TimeframeStudies, This Drug (%)All Drugs %
pre-19908 (10.00)18.7374
1990's25 (31.25)18.2507
2000's28 (35.00)29.6817
2010's16 (20.00)24.3611
2020's3 (3.75)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 63.28

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index63.28 (24.57)
Research Supply Index4.57 (2.92)
Research Growth Index4.83 (4.65)
Search Engine Demand Index103.14 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (63.28)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials6 (6.67%)5.53%
Reviews2 (2.22%)6.00%
Case Studies35 (38.89%)4.05%
Observational0 (0.00%)0.25%
Other47 (52.22%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]